Table II.
Values of vascular, anthropometric, haemodynamic and haemobiochemical parameters for the placebo and SLO groups at weeks 0 and 8.
| Placebo (n=20) | SLO (n=21) | ||||||
|---|---|---|---|---|---|---|---|
| Variable | Week 0 | Week 8 | Change | Week 0 | Week 8 | Change | P-valueb |
| CAVI | 8.66±0.14 | 8.49±0.17 | −0.18±0.10 | 8.60±0.14 | 8.38±0.16 | −0.21±0.11 | 0.800 |
| LDPI (PU) | 0.76±0.02 | 0.68±0.02a | −0.08±0.02 | 0.69±0.02 | 0.70±0.02 | 0.00±0.01 | 0.002 |
| Weight (kg) | 65.4±1.9 | 65.3±1.8 | −0.1±0.3 | 65.7±2.3 | 66.1±2.3 | 0.4±0.2 | 0.150 |
| BMI (kg/m2) | 22.8±0.6 | 22.7±0.6 | −0.02±0.09 | 22.8±0.7 | 22.9±0.7 | 0.15±0.08 | 0.165 |
| Systolic BP (mmHg) | 132±4 | 128±4 | −3.0±2.1 | 133±4 | 127±4 | −5.3±3.2 | 0.563 |
| Diastolic BP (mmHg) | 82±2 | 82±2 | −0.2±1.4 | 83±2 | 81±3 | −2.6±2.0 | 0.319 |
| Heart rate (beats/min) | 69±2 | 67±3 | −2.0±1.8 | 71±2 | 71±2 | −0.1±1.1 | 0.369 |
| Serum total cholesterol (mg/dl) | 217±10 | 217±10 | −0.6±4.3 | 226±5 | 226±9 | −0.4± 8.9 | 0.923 |
| Serum LDL-cholesterol (mg/dl) | 138±8 | 138±8 | 0.1±3.8 | 147±5 | 148±8 | 1.5±8.3 | 0.874 |
| Serum HDL-cholesterol (mg/dl) | 62±3 | 64±3 | 1.7±1.4 | 59±4 | 59±3 | 0.5±1.6 | 0.582 |
| Serum TG (mg/dl) | 112±14 | 99±9 | −13.1±13.7 | 125±13 | 121±12 | −3.7±9.2 | 0.570 |
| Serum glucose (mg/dl) | 92±2 | 93±2 | 1.1±1.4 | 92±1 | 93±2 | 1.2±1.5 | 0.945 |
All values are expressed as the mean ± standard error of the mean.
a
Within-group difference from week 0 (P<0.05).
b
P-value refers to the comparison of within-group changes between the two intervention groups as assessed by analysis of covariance. SLO, shark liver oil; CAVI, cardio-ankle vascular index; LDPI, laser Doppler perfusion imaging; BMI, body mass index; BP, blood pressure; LDL, low-density lipoprotein; HDL, high-density lipoprotein; TG, triglycerides; PU, perfusion units.